The race to a Clostridium difficile vaccine has been dominated by Big Pharmas Sanofi and Pfizer, whose candidates were fast-tracked by the FDA in 2010 and 2014, respectively. Allegheny General Hospital in Pittsburgh announced on Wednesday that it will participate in Phase III trials for Sanofi's investigational vaccine.
On Sept. 18, Advaxis reported "encouraging" data from a Phase II trial of its cervical cancer vaccine, axalimogene filolisbac, dubbed ADXS-HPV. Now, the biotech is reporting an FDA clinical hold on the candidate--5 days after the FDA placed the hold.
Targeting a patient population in the millions, Cambridge, MA-based Genocea this week released results of its genital herpes vaccine hopeful that CEO Chip Clark says affirm the jab's potential to one day break the $1 billion sales mark.
As part of its responsibility to prepare for public health threats, the U.S. Department of Health and Human Services' BARDA unit is seeking more effective influenza vaccines to incorporate into its pandemic strategy. Now, it's funding two projects it hopes will help the state of affairs.
Seeking to accelerate the process of getting new vaccines to market, PRA Health Sciences partnered with the Alliance for Multispecialty Research to look for ways to help vaccine studies run more efficiently and effectively.
Fresh off of a $55 million Series A financing round, Neon Therapeutics jumped into the cancer vaccines space today with the aim of utilizing neoantigen biology to unlock a powerful immune response against the disease.
Less than a month after pairing with the NIAID on a Phase II trial of its universal flu vaccine in the U.S., BiondVax is looking to Hungary for its next trial, this time in conjunction with an overseas public health authority.
Following up on data from a Phase I study in canines with osteosarcoma, Advaxis is taking its HER2 cancer vaccine into human trials.
Novavax's RSV jab protects infants in PhII, nets $89M Gates Foundation grant
Novavax reported on Tuesday that topline results from a Phase II trial in pregnant women showed that its respiratory syncytial virus vaccine protected infants via maternal immunization. It also announced that it won a potential $89 million grant from the Bill & Melinda Gates Foundation to get its candidate through Phase III.
NewLink Genetics won a total of $26.1 million in funding to further the development of its candidate Ebola vaccine from the DOD's Defense Threat Reduction Agency and HHS' BARDA in the span of just over a week. The company has licensed the research, development and manufacturing of the jab to Merck.
GAVI selects next board chair in Ngozi Okonjo-Iweala
The vaccine alliance, GAVI, named Dr. Ngozi Okonjo-Iweala, former Nigerian Minister of Finance, its board chair-elect after an international competitive search process; she'll assume the role in January.
With multidrug-resistant forms of tuberculosis on the rise, and the variable efficacy of the generic BCG vaccine, it is getting harder and harder to treat the disease. The Infectious Disease Research Institute (IDRI) is stepping up to the plate and taking its TB candidate to Phase IIa trials in South Africa.
In June, a team from The Scripps Research Institute in La Jolla, CA, met with federal regulators to discuss human trials for its investigational HIV vaccine. Now, researchers from the Scripps campus in Florida have won a four-year grant of up to $6 million from the Bill & Melinda Gates Foundation to develop a vaccine for HIV/AIDS that researchers there have been working on.
Serum Institute sets out for dengue fast track
Asia's largest vaccinemaker just made a play that could affect the race for a vaccine protecting against dengue fever, a common affliction that has a big impact in the region.
Just 5 months after it scored $21 million of a potential $45 million grant for the development of Ebola treatments, Inovio Pharmaceuticals picked up the remaining $24 million from DARPA, the company announced on Monday. The DOD's Defense Advanced Research Projects Agency chose Inovio to lead the development of Ebola treatments and preventive measures, including a DNA-based vaccine against the disease.
Operating in a field that can leave patients with few options, Advaxis rolled out data for its cervical cancer vaccine this week that represent a "meaningful step" for those afflicted, according to one expert.
On Monday, Takeda announced its participation in WIPO Re:Search, a consortium to accelerate research and development of new drugs, vaccines and diagnostics for malaria and tuberculosis.
There is no licensed vaccine for Group A Streptococcus, which is commonly associated with mild illnesses such as strep throat, but can cause life-threatening disease, including toxic shock syndrome and necrotizing fasciitis. Memphis, TN-based Vaxent and the University of Saskatchewan's Pan-Provincial Vaccine Enterprise (PREVENT) are kicking off Phase I trials for StreptAnova.
For women with triple negative breast cancer, treatment options are limited, and now TapImmune and the Mayo Clinic are looking to change that.
The U.S. may be getting its first adjuvanted flu vaccine. On Tuesday, an FDA panel recommended accelerated approval of Novartis' Fluad--now owned by CSL's flu vaccine subsidiary--in individuals 65 and older.